Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pamela Sears

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|February 20, 2014
Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficileFarah Babakhani, Jaime Seddon, Pamela Sears
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesisIrina Artsimovitch, Jaime Seddon, Pamela Sears
The American Journal of Gastroenterology|October 8, 2014
Response to Surawicz et alSherwood Gorbach, C Andrew DeRyke, Pamela Sears
Journal of Medical Microbiology|February 26, 2011
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficileFarah Babakhani, Abraham Gomez, Nikki Robert, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficileFarah Babakhani, Abraham Gomez, Nikki Robert, et al.
Annals of the New York Academy of Sciences|May 16, 2013
Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibioticPamela Sears, Yoshi Ichikawa, Nancy Ruiz, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|May 24, 2003
An unusual case of multiple papillary fibroelastoma, review of literatureFatima Eslami-Varzaneh, Erwin A Brun, Pamela Sears-Rogan
Infectious Diseases and Therapy|July 22, 2021
Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United StatesYiling Jiang, Eric M Sarpong, Pamela Sears, et al.
Infectious Diseases and Therapy|January 16, 2022
Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United StatesYiling Jiang, Eric M Sarpong, Pamela Sears, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infectionPamela Sears, Derrick W Crook, Thomas J Louie, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|February 20, 2014
Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficileFarah Babakhani, Jaime Seddon, Pamela Sears
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesisIrina Artsimovitch, Jaime Seddon, Pamela Sears
The American Journal of Gastroenterology|October 8, 2014
Response to Surawicz et alSherwood Gorbach, C Andrew DeRyke, Pamela Sears
Journal of Medical Microbiology|February 26, 2011
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficileFarah Babakhani, Abraham Gomez, Nikki Robert, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficileFarah Babakhani, Abraham Gomez, Nikki Robert, et al.
Annals of the New York Academy of Sciences|May 16, 2013
Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibioticPamela Sears, Yoshi Ichikawa, Nancy Ruiz, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|May 24, 2003
An unusual case of multiple papillary fibroelastoma, review of literatureFatima Eslami-Varzaneh, Erwin A Brun, Pamela Sears-Rogan
Infectious Diseases and Therapy|July 22, 2021
Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United StatesYiling Jiang, Eric M Sarpong, Pamela Sears, et al.
Infectious Diseases and Therapy|January 16, 2022
Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United StatesYiling Jiang, Eric M Sarpong, Pamela Sears, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infectionPamela Sears, Derrick W Crook, Thomas J Louie, et al.
Pageof 3